Key result
Antipsychotic treatment in patients with schizophrenia is associated with increased cardiovascular risk factors, including weight gain, dyslipidemia, and diabetes mellitus.
Why the study?
What is the relationship between antipsychotic treatment and cardiovascular disease risk in patients with schizophrenia?
Population
Patients with schizophrenia
Design
Review
Authors
Loading...
May warrant CV risk monitoring with antipsychotics in schizophrenia; confirms excess mortality but leaves optimal mitigation strategies open.
What is the relationship between antipsychotic treatment and cardiovascular disease risk in patients with schizophrenia?
Antipsychotic medications, particularly clozapine and olanzapine, exacerbate cardiovascular risk factors in patients with schizophrenia, highlighting the need for better cardiovascular disease management in this population.
Thomas J. Raedler (2010) conducted a review in Schizophrenia. Antipsychotics was evaluated. Antipsychotic treatment in patients with schizophrenia is associated with increased cardiovascular risk factors, including weight gain, dyslipidemia, and diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: